Turn Therapeutics (NASDAQ:TTRX) Receives Buy Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Turn Therapeutics (NASDAQ:TTRX) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $8.00 price target on the stock.

Separately, Weiss Ratings assumed coverage on shares of Turn Therapeutics in a research note on Monday, January 5th. They issued a “sell (e-)” rating for the company. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.00.

Turn Therapeutics Stock Down 2.3%

Shares of NASDAQ:TTRX opened at $3.34 on Tuesday. The company has a 50 day moving average price of $3.85. Turn Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $26.50. The firm has a market cap of $98.33 million and a P/E ratio of -47.71.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. RVW Wealth LLC bought a new position in Turn Therapeutics in the fourth quarter valued at $71,000. Composition Wealth LLC acquired a new stake in Turn Therapeutics in the 4th quarter valued at $63,000. HighTower Advisors LLC bought a new stake in Turn Therapeutics during the 4th quarter worth about $78,000. Wellington Shields & Co. LLC acquired a new position in shares of Turn Therapeutics during the 4th quarter worth about $259,000. Finally, Geode Capital Management LLC acquired a new position in shares of Turn Therapeutics during the 4th quarter worth about $68,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.